10-K/A: Creative Medical Technology Holdings Files Amended 10-K, Details Executive Compensation and Related Party Transactions

Creative Medical Technology Holdings has filed an amended 10-K report detailing executive compensation, related party transactions, and director information for the fiscal year ended December 31, 2023.

Summary

• Creative Medical Technology Holdings filed an amended annual report on Form 10-K/A for the fiscal year ended December 31, 2023.
• The report details the company's directors, executive officers, and corporate governance practices.
• Executive compensation for CEO Timothy Warbington and CFO Donald Dickerson is outlined, including salaries, option awards, and other compensation.
• The company has employment agreements with both executives, including potential bonuses and severance packages.
• The report also discloses compensation for non-employee directors.
• Information on beneficial ownership of the company's common stock is provided as of April 15, 2024.
• Several related-party transactions are disclosed, including a license agreement with Jadi Cell, a patent purchase from CMH, and a research and development purchase from Narkeshyo LLC.
• The company has a written policy for reviewing and approving related-person transactions.
• The report also details the fees paid to the company's independent auditor, Haynie & Company.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily providing factual information about the company's financials, governance, and related-party transactions. While there are some positive aspects, such as the potential for accelerated development, there are also potential risks associated with related-party transactions.

Positives

• The company has a detailed compensation program for both executives and non-employee directors.
• The acquisition of research tools is expected to significantly accelerate product development and reduce long-term R&D expenses.
• The company has a written policy for reviewing and approving related-person transactions, promoting transparency.
• The company has an audit committee comprised of independent directors with financial expertise.
• The company has a code of ethics that applies to all directors, officers, and employees.

Negatives

• The company has engaged in several related-party transactions, which could raise concerns about potential conflicts of interest.
• The company is obligated to make royalty payments to Jadi Cell and CMH based on the success of certain technologies.
• The company has paid significant amounts for research and development purchases from related parties.

Risks

• The company's reliance on related-party transactions could pose a risk to its financial stability and independence.
• The company's success is dependent on the successful development and commercialization of its technologies, which is subject to regulatory and market risks.
• The company's financial performance is subject to the risks associated with the biotechnology industry, including high research and development costs and the potential for clinical trial failures.
• The company's stock price could be volatile due to the speculative nature of the biotechnology industry.

Future Outlook

The company expects the acquired research tools to accelerate product development and reduce long-term R&D expenses. The company also intends to continue to develop its biological platforms, therapies and products.

Management Comments

• The company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development.
• A third-party analysis of the research tool acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the company's research and development expenses over the long term.

Industry Context

The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. This filing provides insight into how Creative Medical Technology Holdings is navigating these challenges, particularly in the context of its related-party transactions and executive compensation.

Comparison to Industry Standards

• Executive compensation at Creative Medical Technology Holdings appears to be within the range of other small-cap biotechnology companies, with a mix of salary, stock options, and other benefits.
• The company's related-party transactions are not uncommon in the biotechnology industry, where founders and early investors often have ongoing relationships with the company. However, the scale of the transactions, particularly the $5,000,000 research tool purchase, warrants scrutiny.
• The company's reliance on external consultants and related parties for research and development is a common practice in the industry, but it also introduces potential conflicts of interest.
• The company's audit fees of $111,000 are relatively low compared to larger biotechnology companies, which may reflect its smaller size and stage of development.

Related Party Transactions

• The company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by a former director.
• The company acquired a patent from CMH, an affiliate, for the treatment of lower back pain.
• The company purchased research tools for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant is affiliated with.

Stakeholder Impact

• Shareholders should be aware of the company's related-party transactions and their potential impact on the company's financial performance.
• Employees may be impacted by the company's strategic decisions and financial performance.
• Customers and partners may be impacted by the company's product development and commercialization efforts.
• Creditors should be aware of the company's financial obligations and potential risks.

Next Steps

• The company will continue to develop its biological platforms, therapies and products.
• The company will continue to make payments to CMH and Jadi Cell as required by the agreements.
• The company will continue to comply with regulatory requirements.

Key Dates

Keywords

executive compensation, related party transactions, corporate governance, biotechnology, clinical trials, patents, research and development, stem cells, audit committee, financial reporting